Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RHYTHM PHARMACEUTICALS, INC. Director's Dealing 2017

Oct 4, 2017

30849_dirs_2017-10-04_662d06a6-4ec8-4c39-a62b-92a1cba6cc5b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2017-10-04

Reporting Person: MPM BIOVENTURES V, L.P. (10% Owner)
Reporting Person: EVNIN LUKE (10% Owner)
Reporting Person: GADICKE ANSBERT (10% Owner)
Reporting Person: MPM ASSET MANAGEMENT INVESTORS BV5 LLC (10% Owner)
Reporting Person: MPM BIOVENTURES V GP LLC (10% Owner)
Reporting Person: MPM BIOVENTURES V LLC (10% Owner)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 29378 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series A Preferred Stock $ Common Stock (834441) Indirect
Series A-1 Junior Preferred Stock $ Common Stock (1732573) Indirect

Footnotes

F1: Reflects a 1-for-9.17 reverse split effective as of September 29, 2017.

F2: The shares are held as follows: 28,280 by MPM BioVentures V, L.P. ("BV V") and 1,098 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 3. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F3: Each share of Series A Preferred Stock and Series A-1 Junior Preferred Stock is convertible into 0.10905125 of a share of Common Stock without payment of further consideration and will automatically convert into 0.10905125 of a share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The
shares have no expiration date.

F4: The shares are held as follows: 803,237 by BV V and 31,204 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F5: The shares are held as follows: 1,667,782 by BV V and 64,791 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.